Disclosures
16
protease inhibitor BI 201335 results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors
description
Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors. Disclosures. Introduction. SILEN-C1 trial. Virologic response a. Methods. - PowerPoint PPT Presentation
Transcript of Disclosures
Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates:
Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors
Disclosures
Introduction
SILEN-C1 trial
Virologic responsea
Methods
Baseline characteristics
Virologic response by age and gender
Virologic response by baseline ALT and GGT
Virologic response by baseline HCV RNA
Virologic response by HCV GT-1 subtype
Virologic response by IL28B
Baseline predictors of SVR
Baseline predictors of SVR
Discussion
Acknowledgements
